Richardpruen (talk | contribs) (Added K. Fagerstrom paper) |
(HIV) |
||
| Line 616: | Line 616: | ||
='''HIV/AIDS'''= <!--T:120--> | ='''HIV/AIDS'''= <!--T:120--> | ||
===2022: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908735/ Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): A Feasibility Trial of Nicotine Vaping Products for Smoking Cessation Among People Living with HIV]=== | |||
*This study found that the provision of NVPs for 12 weeks was associated with 7-day point prevalence tobacco smoking abstinence among 35% of a sample of PLHIV who smoked tobacco daily. These findings suggest that NVPs represent a potentially feasible and effective short-to-medium term tobacco smoking cessation aid and/or tobacco harm reduction strategy among PLHIV. | |||
<br> | <br> | ||
edits